|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/16/21 Biocept Inc. 10-Q 6/30/21 71:9.7M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.13M
2: EX-10.2 Material Contract HTML 259K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
13: R1 Document and Entity Information HTML 74K
14: R2 Condensed Balance Sheets HTML 98K
15: R3 Condensed Balance Sheets (Parenthetical) HTML 39K
16: R4 Condensed Statements of Operations and HTML 94K
Comprehensive Income/(Loss) (Unaudited)
17: R5 Condensed Statements of Shareholders' Equity HTML 119K
(Unaudited)
18: R6 Condensed Statements of Cash Flows (Unaudited) HTML 95K
19: R7 Condensed Statements of Cash Flows (Unaudited) HTML 41K
(Parenthetical)
20: R8 The Company, Business Activities and Basis of HTML 158K
Presentation
21: R9 Liquidity HTML 29K
22: R10 Sales of Equity Securities HTML 29K
23: R11 Fair Value Measurement HTML 35K
24: R12 Balance Sheet Details HTML 92K
25: R13 Leases HTML 201K
26: R14 Stock-Based Compensation HTML 156K
27: R15 Common Stock Warrants Outstanding HTML 62K
28: R16 Net Loss per Common Share HTML 46K
29: R17 Commitments and Contingencies HTML 26K
30: R18 Related Party Transactions HTML 27K
31: R19 Subsequent Events HTML 24K
32: R20 The Company, Business Activities and Basis of HTML 164K
Presentation (Policies)
33: R21 The Company, Business Activities and Basis of HTML 129K
Presentation (Tables)
34: R22 Fair Value Measurement (Tables) HTML 30K
35: R23 Balance Sheet Details (Tables) HTML 91K
36: R24 Leases (Tables) HTML 199K
37: R25 Stock-Based Compensation (Tables) HTML 158K
38: R26 Common Stock Warrants Outstanding (Tables) HTML 61K
39: R27 Net Loss per Common Share (Tables) HTML 44K
40: R28 The Company, Business Activities and Basis of HTML 57K
Presentation - Additional Information (Detail)
41: R29 The Company, Business Activities and Basis of HTML 39K
Presentation - Composition of Net Revenues
Recognized Disaggregated by Source (Detail)
42: R30 The Company, Business Activities and Basis of HTML 36K
Presentation - Composition of Net Revenues
Recognized Disaggregated by Nature (Detail)
43: R31 The Company, Business Activities and Basis of HTML 43K
Presentation - Summary of Third-Party Payers That
Represent More Than 10% of Total Net Revenues and
Total Net Accounts Receivable and Their Related
Percentage (Detail)
44: R32 Liquidity - Additional Information (Detail) HTML 68K
45: R33 Sales of Equity Securities - Additional HTML 67K
Information (Detail)
46: R34 Fair Value Measurement - Additional Information HTML 53K
(Detail)
47: R35 Fair Value Measurement - Assumptions Used for HTML 42K
Determining Fair Values of Common Stock Warrants
(Detail)
48: R36 Balance Sheet Details - Schedule of Fixed Assets HTML 68K
and Accrued Liabilities (Detail)
49: R37 Leases - Additional Information (Detail) HTML 135K
50: R38 Leases - Schedule of Right-Of-Use Lease Assets HTML 27K
(Detail)
51: R39 Leases - Schedule of Current Portion of Operating HTML 27K
and Finance Lease Liabilities (Detail)
52: R40 Leases - Schedule of Long-Term Portion of HTML 27K
Operating and Finance Lease Liabilities (Detail)
53: R41 Leases - Schedule of Lease Expense (Detail) HTML 31K
54: R42 Leases - Schedule of Remaining Future Minimum HTML 71K
Lease Payments for Finance and Operating Leases
(Detail)
55: R43 Leases - Supplemental Cash Flow Information HTML 28K
Related to Operating and Finance Leases (Detail)
56: R44 Stock-Based Compensation - Additional Information HTML 69K
(Detail)
57: R45 Stock-Based Compensation - Summary of Stock Option HTML 52K
Activity (Detail)
58: R46 Stock-Based Compensation - Assumptions Used for HTML 40K
Determining Fair Value of Stock Options Under
Black-Scholes Pricing Model (Detail)
59: R47 Stock-Based Compensation - Summary of RSU Activity HTML 47K
(Detail)
60: R48 Stock-Based Compensation - Effects of Stock-Based HTML 36K
Compensation Related to Equity Awards to Employees
and Non-employees on Condensed Statement of
Operations and Comprehensive Loss (Detail)
61: R49 Common Stock Warrants Outstanding - Summary of HTML 37K
Equity-Classified Common Stock Warrant Activity
(Detail)
62: R50 Common Stock Warrants Outstanding - Additional HTML 40K
Information (Detail)
63: R51 Net Loss per Common Share - Additional Information HTML 28K
(Detail)
64: R52 Net Loss per Common Share - Schedule of HTML 34K
Anti-Dilutive Securities Excluded from
Computations of Diluted Weighted-Average Shares
(Detail)
65: R53 Commitments and Contingencies - Additional HTML 30K
Information (Detail)
66: R54 Related Party Transactions - Additional HTML 44K
Information (Detail)
67: R55 Subsequent Events - Additional Information HTML 32K
(Detail)
69: XML IDEA XML File -- Filing Summary XML 127K
12: XML XBRL Instance -- bioc-10q_20210630_htm XML 2.19M
68: EXCEL IDEA Workbook of Financial Reports XLSX 89K
8: EX-101.CAL XBRL Calculations -- bioc-20210630_cal XML 167K
9: EX-101.DEF XBRL Definitions -- bioc-20210630_def XML 540K
10: EX-101.LAB XBRL Labels -- bioc-20210630_lab XML 1.28M
11: EX-101.PRE XBRL Presentations -- bioc-20210630_pre XML 937K
7: EX-101.SCH XBRL Schema -- bioc-20210630 XSD 205K
70: JSON XBRL Instance as JSON Data -- MetaLinks 341± 535K
71: ZIP XBRL Zipped Folder -- 0001564590-21-044664-xbrl Zip 307K
EXHIBIT 31.1
CERTIFICATION
I, Michael W. Nall, certify that:
|
1. |
I have reviewed this Quarterly Report on Form 10-Q of Biocept, Inc.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: August 16, 2021
|
/s/ Michael W. Nall |
|
President and Chief Executive Officer (Principal Executive Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/16/21 | 8-K | ||
| For Period end: | 6/30/21 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/15/22 Biocept Inc. 10-Q/A 9/30/21 75:10M ActiveDisclosure/FA 11/16/21 Biocept Inc. S-8 11/16/21 3:185K ActiveDisclosure/FA 11/15/21 Biocept Inc. 10-Q 9/30/21 70:9.4M ActiveDisclosure/FA |